What does Cadrenal Therapeutics do?
Cadrenal Therapeutics, Inc. is a Nasdaq-listed clinical-stage biotechnology company developing anticoagulant and antithrombotic therapies for rare or high-risk cardiovascular settings. It has no approved product and reports as one operating segment, so value depends on clinical success, partnerships, and eventual commercialization.
Which clinical problems define the company?
CAD-1005 is an intravenous 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, an immune reaction that can cause dangerous clotting. Frunexian is an IV Factor XIa inhibitor for cardiac-surgery patients susceptible to HIT. Tecarfarin is an oral vitamin K antagonist for populations in which warfarin metabolism or interactions are problematic. CAD-2000 is a preclinical oral 12-LOX follow-on.
Why does this narrow focus matter?
Cadrenal targets underserved cardiac acute and critical-care settings rather than the broad anticoagulation market. The company overview emphasizes life-threatening immune and thrombotic conditions. This focus can attract specialized partners, but a setback in one program can alter the portfolio.
| Identity item | Cadrenal profile | Analytical implication |
|---|---|---|
| Company type | Clinical-stage biotechnology | No operating revenue base supports a conventional earnings analysis. |
| Core field | Anticoagulation and antithrombotic medicine | Clinical differentiation, safety, and hospital adoption matter more than near-term sales growth. |
| Customers if approved | Hospitals, cardiac centers, specialists, and specialty distributors | Commercialization would require focused medical affairs, reimbursement, and institutional access. |
| Current reporting structure | One segment | Program-level milestones, rather than segment revenue, are the key unit of analysis. |
How does Cadrenal make money before product approval?
Cadrenal earns no product revenue. Equity sales, at-the-market issuance, and warrant exercises fund clinical development, regulatory work, acquired-program obligations, and public-company overhead. Future economics could include licensing fees, milestones, royalties, or commercial sales, but none is established today.
What are the realistic future revenue streams?
The July 2026 update launched a process for out-licensing, portfolio monetization, and co-development. A partner could provide non-dilutive cash, share trial costs, and add hospital capabilities, but would retain part of future economics. Direct commercialization preserves more upside while requiring far more capital.
| Economic route | Current status | What would create value | Main trade-off |
|---|---|---|---|
| Equity and warrants | Primary funding source | Extends runway to reach clinical milestones | Dilutes existing shareholders and can create an overhang. |
| Out-licensing | Structured process announced in July 2026 | Upfront cash, milestones, and royalties | Cadrenal gives up part of future economics and control. |
| Co-development | Strategic objective | Shared trial cost and commercial capabilities | Negotiation terms depend heavily on data quality and timing. |
| Commercial sales | Not available; no approved product | Hospital use, pricing, reimbursement, and repeat institutional demand | Requires approval, manufacturing readiness, market access, and working capital. |
Why is cash runway part of the business model?
Financing determines which trials can start and how much leverage management has with partners. The July 2026 strategic alignment organized the portfolio into three acute-care pillars and made partnering a capital-allocation priority.
Which pipeline assets matter most?
The portfolio is a set of probability-weighted projects. CAD-1005 is the principal value driver because it has clinical evidence, regulatory designations, and an FDA-supported late-stage path. Frunexian and tecarfarin add breadth but require more development and financing; CAD-2000 is longer-dated optionality.
Why is CAD-1005 the central asset?
Cadrenal acquired CAD-1005 in December 2025 after two Phase 1 studies and a blinded, placebo-controlled Phase 2 trial in 24 patients. The Phase 2 results showed fewer thrombotic events but no platelet-recovery difference. The small study requires Phase 3 confirmation.
FDA feedback supported a randomized, blinded, placebo-controlled Phase 3 study of approximately 120 patients, with thrombotic events as the primary endpoint and a planned interim analysis. CAD-1005 has U.S. Orphan Drug and Fast Track designations plus European orphan status. The April 2026 FDA update defines a path but does not guarantee efficacy or approval.
How do frunexian and tecarfarin change the portfolio?
Frunexian adds a second acute-care mechanism around cardiac surgery. Tecarfarin addresses chronic oral anticoagulation where warfarin metabolism or kidney-related complexity is problematic. Together they strengthen the specialty narrative but compete for scarce capital, forcing management to fund, partner, sequence, or monetize programs selectively.
| Program | Mechanism / route | Lead use case | Stage signal | Key dependency |
|---|---|---|---|---|
| CAD-1005 | 12-LOX inhibitor, IV | Treatment of HIT | Phase 3-ready after FDA meeting | Financing, protocol execution, enrollment, and confirmation of thrombotic benefit. |
| Frunexian | Factor XIa inhibitor, IV | CABG patients susceptible to HIT | Phase 2-ready | Partnering and proof that the peri-operative profile is differentiated. |
| Tecarfarin | Vitamin K antagonist, oral | High-risk chronic anticoagulation | Phase 3-ready | Indication selection, trial funding, and evidence of advantage over established options. |
| CAD-2000 | 12-LOX inhibitor, oral | Follow-on platform opportunity | Preclinical | Translational evidence and capital after higher-priority programs. |
What did the latest quarter and financing show?
Q1 2026 spending and net loss declined year over year, but liquidity remained the central issue. Cash fell to $2.3 million, and management said available funds could not support planned trials or twelve months of operations. The Q1 2026 Form 10-Q raised substantial doubt about continued operations.
What changed versus the prior-year quarter?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| General and administrative expense | $1.7M | $2.3M | Lower professional and corporate expense reduced the quarterly burn. |
| Research and development expense | $0.8M | $1.7M | Spending fell while the company prepared late-stage plans rather than running a major trial. |
| Total operating expense | $2.5M | $3.9M | A 36% decline improved near-term cash preservation. |
| Net loss | $2.5M | $3.8M | The loss narrowed 35%, but the company remained pre-revenue. |
| Basic and diluted loss per share | $(1.04) | $(2.09) | The change reflects both the smaller loss and a higher weighted-average share count. |
| Cash used in operating activities | $3.0M | $4.6M | Burn improved, but still exceeded quarter-end cash before subsequent financing. |
How did subsequent financings alter the runway?
April warrant exercises generated about $2.5 million of gross proceeds. A June transaction added pre-funded and common-stock warrants; the financing release described $3.0 million upfront and expected runway into Q1 2027. Potential warrant proceeds should not be treated as cash until exercised.
How did Cadrenal’s strategy evolve into a critical-care franchise?
Cadrenal began with tecarfarin, then acquired acute-care assets and repositioned around cardiac critical care. The current story therefore reflects a newly assembled portfolio, contingent payments, and a sharper need to prioritize capital.
Which turning points still shape the company today?
-
2022Company formation. Cadrenal was incorporated in Delaware to develop therapies for cardiovascular populations with unmet anticoagulation needs.
-
Jan. 2023Nasdaq IPO. The company sold 1.4 million shares at $5.00 for $7.0 million of gross proceeds, establishing public-market access but a modest capital base. The terms appear in the IPO filing.
-
Mar. 2025Abbott collaboration support. Abbott agreed to support trial design and site identification for a tecarfarin study in HeartMate 3 LVAD patients, adding device-market expertise without converting the program into a funded commercial partnership.
-
Sep. 2025Frunexian acquisition. Cadrenal added a Phase 2-ready IV Factor XIa program, expanding from chronic oral anticoagulation into peri-operative acute care. The acquisition filing also created future milestone and royalty obligations.
-
Dec. 2025CAD-1005 acquisition. The company acquired the 12-LOX program and made HIT its lead late-stage opportunity. The acquisition announcement described two completed Phase 1 studies and an existing Phase 2 data set.
-
Apr. 2026Late-stage regulatory alignment. FDA feedback supported a controlled Phase 3 path for CAD-1005, moving the central question from trial design toward funding and execution.
-
Jul. 2026Portfolio monetization process. Management organized the assets into pre-operative, orphan-acceleration, and post-operative pillars and began seeking licensing or co-development structures.
What gives Cadrenal a competitive edge—and what does not?
Cadrenal’s potential advantage is scientific and regulatory, not commercial. It controls differentiated mechanisms in narrow indications but has no approved product, sales force, manufacturing scale, or recurring revenue. Any moat remains conditional on successful trials, intellectual property, approval, and hospital adoption.
Where could a real moat emerge?
CAD-1005 may benefit from a first-in-class 12-LOX position, orphan economics, Fast Track interaction, and human safety data. Tecarfarin may differentiate through metabolism less exposed to CYP450 variability and renal impairment, while frunexian adds another mechanism for heparin-risk patients. These resources matter only if proprietary, clinically validated, and hard to substitute.
Which alternatives define the competitive market?
The main competitors are established therapies and clinical protocols. CAD-1005 must improve on non-heparin HIT management; frunexian must fit cardiac-surgery workflows with little tolerance for bleeding or thrombosis; tecarfarin must justify switching from familiar oral options. Hospitals, physicians, payers, and regulators hold substantial power.
| Program | Main alternative | Potential differentiator | Evidence still required |
|---|---|---|---|
| CAD-1005 | Argatroban, bivalirudin, and other non-heparin management | Targets platelet-driven thrombosis through 12-LOX while standard anticoagulation continues | Phase 3 efficacy, safety, operational feasibility, and persuasive net benefit. |
| Frunexian | Existing peri-operative anticoagulation protocols | Factor XIa inhibition may separate thrombosis control from bleeding risk | Controlled clinical evidence in the intended cardiac-surgery population. |
| Tecarfarin | Warfarin and other oral anticoagulant options | Alternative metabolism for patients with renal disease, multiple drugs, or devices | A funded pivotal program, regulatory clarity, and an adoption case strong enough to change practice. |
Who owns CVKD stock, and how is the company governed?
Cadrenal uses one-share, one-vote common stock, but insider influence is meaningful. The 2025 definitive proxy, measured July 28, 2025, showed CEO and Chairman Quang Pham at 20.58% beneficial ownership and all directors and executives at 26.09%. Later financings diluted those historical percentages, which are best read as governance context.
What does the ownership table signal?
| Holder / group | Beneficial ownership | Source period | Why it matters |
|---|---|---|---|
| Quang Pham, CEO and Chairman | 421,875 shares; 20.58% | July 28, 2025 | Founder-level economic exposure aligns management with long-term outcomes but concentrates influence. |
| PVBQ Living Trust | 200,000 shares; 9.77% | July 28, 2025 | The trust was included in Pham’s beneficial ownership, reinforcing the founder-linked voting block. |
| All directors and executive officers | 548,796 shares; 26.09% | July 28, 2025 | Insiders could influence director elections, financing approvals, and strategic transactions. |
| Other stockholders | Dispersed balance | July 28, 2025 | Public investors bear dilution from subsequent offerings while having no separate control class. |
These figures come from the 2025 definitive proxy statement. They should not be combined mechanically with the 2026 share count because options, warrants, equity sales, and pre-funded warrants changed the capital structure.
How should investors interpret the board structure?
The July 2026 preliminary proxy proposed a equity plan and approval for shares underlying new warrants. Governance directly affects dilution and financing capacity.
Which KPIs and valuation drivers matter most?
Earnings multiples are not useful primary indicators. Track clinical probability, regulatory timing, cash burn, financing, dilution, and risk-adjusted asset cash flows.
What should a research dashboard track?
| KPI | How to interpret it | Current anchor | Why it changes value |
|---|---|---|---|
| CAD-1005 Phase 3 activation | Protocol finalization, funding, site initiation, and first patient dosed | FDA-supported design; trial not yet funded in Q1 filing | Moves the asset from planning risk into execution risk. |
| Runway | Cash divided by normalized quarterly burn, adjusted for committed trial spending | Company expected runway into Q1 2027 after June financing | Determines bargaining power and the probability of another near-term raise. |
| Quarterly operating cash use | Cash consumed by operations before financing | $3.0M in Q1 2026 | Shows how quickly available capital converts into development progress. |
| Fully diluted share exposure | Common shares plus in-the-money warrants, pre-funded warrants, and options | Material warrant issuance in April and June 2026 | Changes value per share even when enterprise value is unchanged. |
| Partner economics | Upfront cash, cost share, milestones, royalties, territorial rights | Structured partnering process launched July 2026 | Can reduce financing risk while transferring part of future upside. |
| Clinical effect and safety | Thrombotic-event reduction, bleeding, serious adverse events, and discontinuations | Phase 2 signal above 25% absolute reduction in thrombotic events | Drives probability of approval, labeling, adoption, and pricing. |
Why is a probability-adjusted model more appropriate than a standard DCF?
A steady-state DCF would imply predictable revenue. A risk-adjusted model estimates patients, penetration, price, cost, timing, and exclusivity by program. Probability-weighted cash flows are reduced by development costs, adjusted for corporate obligations, and divided by fully diluted shares.
Key sensitivities are CAD-1005 Phase 3 success, trial timing, financing, and partner economics. Terminal value deserves less weight than for a mature company. Each acquired clinical program can also require up to $15 million of milestones.
What opportunities and risks could change the story?
A successful partnership or pivotal trial could validate the platform and reduce financing risk. The downside is concentrated because Cadrenal has no commercial cash flow, a going-concern warning, and several programs competing for capital. Balance-sheet durability determines whether Cadrenal captures scientific value.
Which risks deserve the most attention?
What is the key takeaway from Cadrenal Therapeutics analysis?
Cadrenal is a founder-led biotechnology portfolio focused on specialized anticoagulation. CAD-1005 is the clearest value driver because it combines a differentiated mechanism, Phase 2 evidence, regulatory designations, and an FDA-supported pivotal design. Frunexian and tecarfarin add breadth; CAD-2000 adds longer-dated optionality.
Financially, Cadrenal was pre-revenue and under a Q1 2026 going-concern warning. Warrant financings extended runway but increased dilution and did not fund every planned trial. Valuation must separate the programs and make timing, contingent payments, and fully diluted shares explicit.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.